News

DEA-Led 'Operation Cyber Juice' to Target Underground Steroid Labs

The Drug Enforcement Agency (DEA) officials introduced Operation Cyber Juice, a multi-agency collaboration law enforcement action targeting every level of the global underground anabolic steroids and other performance-enhancing drugs.

Hospitalized Infection Risk for Biologics in RA Compared

For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab vs. abatacept.

Finerenone Promising for Albuminuria in Diabetic Nephropathy

For patients with diabetic nephropathy receiving an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, the addition of finerenone results in improvement in the urinary albumin-creatinine ratio (UACR).

Simponi Aria Label to Include Data on Patient Outcomes

Janssen Biotech announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the label for Simponi Aria (golimumab for infusion) to include measures in both physical and emotional health in patients being treated for moderately to severely active rheumatoid arthritis (RA).

Too Much TV Could Lead to PE, Say Researchers

Could watching too much television be deadly? A new study presented at the European Society of Cardiology Congress 2015 meeting is the first to examine the association between prolonged television watching and fatal pulmonary embolism (PE).

New Analysis on Risk of Heart Failure With DPP-4 Inhibitor

A new analysis showed that patients with type 2 diabetes and cardiovascular disease with a history of heart failure could still take sitagliptin without an increased risk of cardiovascular complications.

For Resistant Hypertension, Adding This Drug Significantly Lowered BP

For patients with resistant hypertension, adding spironolactone was significantly more effective than adding other antihypertensives, researchers presented at the European Society of Cardiology Congress 2015.

New Oral Antiemetic Agent Gains FDA Approval

Tesaro announced that the Food and Drug Administration (FDA) has approved Varubi (rolapitant) tablets in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic chemotherapy.

Emend Now Approved for Pediatric Patients

The Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Emend (aprepitant; Merck) to include patients 12-17 years old and patients <12 years old who weigh at least 30kg.

New Efficacy Data, Infusion Time for Antibiotic Teflaro

Allergan announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the label for Teflaro (ceftaroline fosamil; Forest) for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).